Literature DB >> 22286749

Small nerve fibres, small hands and small feet: a new syndrome of pain, dysautonomia and acromesomelia in a kindred with a novel NaV1.7 mutation.

Janneke G J Hoeijmakers1, Chongyang Han, Ingemar S J Merkies, Lawrence J Macala, Giuseppe Lauria, Monique M Gerrits, Sulayman D Dib-Hajj, Catharina G Faber, Stephen G Waxman.   

Abstract

The Na(V)1.7 sodium channel is preferentially expressed within dorsal root ganglion and sympathetic ganglion neurons and their small-diameter peripheral axons. Gain-of-function variants of Na(V)1.7 have recently been described in patients with painful small fibre neuropathy and no other apparent cause. Here, we describe a novel syndrome of pain, dysautonomia, small hands and small feet in a kindred carrying a novel Na(V)1.7 mutation. A 35-year-old male presented with erythema and burning pain in the hands since early childhood, later disseminating to the feet, cheeks and ears. He also experienced progressive muscle cramps, profound sweating, bowel disturbances (diarrhoea or constipation), episodic dry eyes and mouth, hot flashes, and erectile dysfunction. Neurological examination was normal. Physical examination was remarkable in revealing small hands and feet (acromesomelia). Blood examination and nerve conduction studies were unremarkable. Intra-epidermal nerve fibre density was significantly reduced compared to age- and sex-matched normative values. The patient's brother and father reported similar complaints including distal extremity redness and pain, and demonstrated comparable distal limb under-development. Quantitative sensory testing revealed impaired warmth sensation in the proband, father and brother. Genetic analysis revealed a novel missense mutation in the SCN9A gene encoding sodium channel Na(V)1.7 (G856D; c.2567G > A) in all three affected subjects, but not in unaffected family members. Functional analysis demonstrated that the mutation hyperpolarizes (-9.3 mV) channel activation, depolarizes (+6.2 mV) steady-state fast-inactivation, slows deactivation and enhances persistent current and the response to slow ramp stimuli by 10- to 11-fold compared with wild-type Na(V)1.7 channels. Current-clamp analysis of dorsal root ganglion neurons transfected with G856D mutant channels demonstrated depolarized resting potential, reduced current threshold, increased repetitive firing in response to suprathreshold stimulation and increased spontaneous firing. Our results demonstrate that the G856D mutation produces DRG neuron hyperexcitability which underlies pain in this kindred, and suggest that small peripheral nerve fibre dysfunction due to this mutation may have contributed to distal limb under-development in this novel syndrome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286749     DOI: 10.1093/brain/awr349

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  25 in total

1.  Extending the clinical spectrum of pain channelopathies.

Authors:  Henry Houlden
Journal:  Brain       Date:  2012-02       Impact factor: 13.501

2.  Inherited pain: sodium channel Nav1.7 A1632T mutation causes erythromelalgia due to a shift of fast inactivation.

Authors:  Mirjam Eberhardt; Julika Nakajima; Alexandra B Klinger; Cristian Neacsu; Kathrin Hühne; Andrias O O'Reilly; Andreas M Kist; Anne K Lampe; Kerstin Fischer; Jane Gibson; Carla Nau; Andreas Winterpacht; Angelika Lampert
Journal:  J Biol Chem       Date:  2013-12-05       Impact factor: 5.157

3.  Reverse pharmacogenomics: carbamazepine normalizes activation and attenuates thermal hyperexcitability of sensory neurons due to Nav 1.7 mutation I234T.

Authors:  Yang Yang; Talia Adi; Philip R Effraim; Lubin Chen; Sulayman D Dib-Hajj; Stephen G Waxman
Journal:  Br J Pharmacol       Date:  2017-07-30       Impact factor: 8.739

Review 4.  Regulating excitability of peripheral afferents: emerging ion channel targets.

Authors:  Stephen G Waxman; Gerald W Zamponi
Journal:  Nat Neurosci       Date:  2014-01-28       Impact factor: 24.884

Review 5.  The role of sodium channels in painful diabetic and idiopathic neuropathy.

Authors:  Giuseppe Lauria; Dan Ziegler; Rayaz Malik; Ingemar S J Merkies; Stephen G Waxman; Catharina G Faber
Journal:  Curr Diab Rep       Date:  2014-10       Impact factor: 4.810

6.  Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia.

Authors:  David R Witty; Giuseppe Alvaro; Dominique Derjean; Gerard M P Giblin; Kevin Gunn; Charles Large; David T Macpherson; Valerie Morisset; Davina Owen; Joanne Palmer; Francois Rugiero; Simon Tate; Christopher A Hinckley; Himanshu Naik
Journal:  ACS Med Chem Lett       Date:  2020-07-16       Impact factor: 4.345

7.  The Domain II S4-S5 Linker in Nav1.9: A Missense Mutation Enhances Activation, Impairs Fast Inactivation, and Produces Human Painful Neuropathy.

Authors:  Chongyang Han; Yang Yang; Bianca T A de Greef; Janneke G J Hoeijmakers; Monique M Gerrits; Camiel Verhamme; Jian Qu; Giuseppe Lauria; Ingemar S J Merkies; Catharina G Faber; Sulayman D Dib-Hajj; Stephen G Waxman
Journal:  Neuromolecular Med       Date:  2015-03-20       Impact factor: 3.843

8.  Gain-of-function mutation of a voltage-gated sodium channel NaV1.7 associated with peripheral pain and impaired limb development.

Authors:  Brian S Tanaka; Phuong T Nguyen; Eray Yihui Zhou; Yong Yang; Vladimir Yarov-Yarovoy; Sulayman D Dib-Hajj; Stephen G Waxman
Journal:  J Biol Chem       Date:  2017-04-05       Impact factor: 5.157

9.  Ca2+ toxicity due to reverse Na+/Ca2+ exchange contributes to degeneration of neurites of DRG neurons induced by a neuropathy-associated Nav1.7 mutation.

Authors:  M Estacion; B P S Vohra; S Liu; J Hoeijmakers; C G Faber; I S J Merkies; G Lauria; J A Black; S G Waxman
Journal:  J Neurophysiol       Date:  2015-07-08       Impact factor: 2.714

10.  Genetic Variation and Hot Flashes: A Systematic Review.

Authors:  Carolyn J Crandall; Allison L Diamant; Margaret Maglione; Rebecca C Thurston; Janet Sinsheimer
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.